Newsbenzinga
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab
· Published
Article summary
AstraZeneca invests $2 billion in Summit Therapeutics to combine cancer drugs ivonescimab and Sone-Ve.
An excerpt from the original article.
Comments —
Loading comments…